Project HOME: Home-Based Treatment Options and Mechanisms for Eating Disorders

Sponsor
University of Pittsburgh (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05184556
Collaborator
National Institute of Mental Health (NIMH) (NIH), Lifespan (Other), Rhode Island College (Other)
60
3
2
22
20
0.9

Study Details

Study Description

Brief Summary

This randomized, controlled effectiveness trial will assess outcomes, implementation, and mechanisms of two psychological treatments for adolescent anorexia nervosa (AN) delivered in the home setting, in the context of community-based mental health. Adolescents with AN-spectrum disorders (n=50) and their caregivers will be randomly assigned to either family-based treatment or integrated family therapy delivered in the home. Caregivers and adolescents will provide data on weight, eating, and putative treatment mechanisms, including caregiver self-efficacy, adolescent distress, and generalizability of treatment skills. Treatment feasibility, acceptability, and appropriateness will be measured among providers and participating families. The proposed study has clear potential to advance scientific and clinical understanding of the real-world effectiveness of psychological treatments for AN, including whether adapting them for the home setting may improve accessibility and effects on treatment outcome

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Family-based treatment (FBT)
  • Behavioral: Integrative family therapy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Project HOME: Home-Based Treatment Options and Mechanisms for Eating Disorders
Actual Study Start Date :
Apr 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Jan 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Family-based treatment

Families will complete 2-6 hours of therapy per week for 10 - 32 weeks, on average, determined by clinical need in conjunction with insurance specifications related to coverage of home-based care

Behavioral: Family-based treatment (FBT)
FBT is a structured behavioral treatment focused on empowering caregivers to take charge of the adolescent's eating behavior and return him/her to a normative weight and developmental trajectory. FBT involves three consecutive phases: 1) caregivers are fully in control of the adolescent's eating; 2) control of eating is gradually returned to the adolescent; and 3) developmental issues are explored. In the current study, FBT is adapted for delivery in the home setting in the following ways: intensified dose of treatment (2-6 hours of therapy per week over 10 - 32 weeks); use of clinician as an additional support to the family; multiple family meals in the home and community; sociocultural tailoring; and inclusion of supplemental individual work with the adolescent to improve emotion regulation/distress tolerance.

Active Comparator: Integrative family therapy

Families will complete 2-6 hours of therapy per week for 10 - 32 weeks, on average, determined by clinical need in conjunction with insurance specifications related to coverage of home-based care

Behavioral: Integrative family therapy
The integrated family therapy approach includes psychoeducation, supportive family therapy, and elements of cognitive-behavioral interventions. Families may be referred for additional nutritional counseling and prescribed a meal plan as indicated. Typical strategies include educating families on the presentation and prognosis of adolescent AN; identifying dysfunctional family structures/alliances and communication patterns; using reflective listening to engage and validate family members; challenging maladaptive beliefs about eating and weight; and supporting families in developing strategies for management of both general and eating disorder-specific distress. Treatment is generally non-directive.

Outcome Measures

Primary Outcome Measures

  1. Body mass index percentile [Up to 24-weeks post randomization]

    Adolescents will have their height and weight measured to calculate BMI percentile using CDC growth charts and accompanying procedures.

  2. Eating Disorder Examination [Up to 24-weeks post randomization]

    The Eating Disorder Examination will be used to diagnose anorexia nervosa, and assess eating disorder behaviors, attitudes, and cognitions. Items are scored from 0-7 and averaged to create subscales reflecting restraint, eating concerns, shape concerns, weight concerns, and global eating-related psychopathology. Higher scores indicate more severe eating disorder symptoms.

Secondary Outcome Measures

  1. Abbreviated Acceptability Rating Profile [Up to 24-weeks post randomization]

    The Abbreviated Acceptability Rating Profile is an 8-item questionnaire that assesses acceptability of treatment from both parent and child viewpoints on a 6-point Likert scale. Higher scores reflect greater levels of treatment acceptability.

  2. Therapy Suitability and Patient Expectancy [Up to 24-weeks post randomization]

    The Therapy Suitability and Patient Expectancy is used to assess patients' and caregivers' perceptions of treatment suitability and expected improvement with treatment from 0 (not at all) to 10 (extremely) using 2 items. Higher scores reflect more positive expectations from treatment.

  3. Acceptability, Appropriateness, and Feasibility of Intervention Measure [Up to 3 years]

    The Acceptability, Appropriateness, and Feasibility of Intervention Measure is a 31-item survey comprising three subscales (acceptability, appropriateness, and feasibility) that will assess clinician perspectives of treatment. Higher scores reflect greater perceived acceptability, appropriateness, and feasibility.

  4. Client Satisfaction Questionnaire [Up to 24-weeks post randomization]

    The Client Satisfaction Questionnaire-8 is an 8-item questionnaire that assesses satisfaction with treatment on a 4-point Likert scale, with higher scores indicating higher treatment satisfaction.

  5. Multi-theoretical List of Therapeutic Interventions [Up to 24-weeks post randomization]

    The Multi-theoretical List of Therapeutic Interventions assesses different therapeutic techniques occurring across different forms of psychotherapy. The MULTI-60 comprises 8 subscales representing 8 primary therapeutic orientations, including cognitive-behavioral and dialectic-behavioral therapy. Items are rated from 1-5, with higher scores indicating that a given technique is more typical of the overall treatment approach.

  6. Therapeutic Technique Scale [Up to 3 years]

    The Therapeutic Technique Scale assesses clinician implementation of 17 therapeutic techniques to measure treatment fidelity. Items are rated from 0-5, with higher scores indicating a greater level of skill in implementing each therapeutic technique in therapy sessions.

  7. Engagement [Up to 3 years]

    Percentage of potentially eligible families offered treatment who ultimately engaged in a baseline assessment visit.

  8. Enrollment [Up to 3 years]

    Percentage of potentially eligible families who ultimately enroll in the treatment.

  9. Attendance [Up to 24-weeks post randomization]

    Number of therapy sessions completed.

  10. Completion [Up to 24-weeks post randomization]

    Percentage of families who complete a course of treatment without terminating or being withdrawn prematurely.

Other Outcome Measures

  1. Subjective Units of Distress Scale [Up to 24-weeks post randomization]

    The Subjective Units of Distress Scale is a widely-used therapeutic and clinical tool used to measure state anxiety, typically in the context of therapy or treatment sessions. Distress is rated on a 0-100 scale with higher scores reflecting greater state anxiety/distress.

  2. Parent vs. Anorexia Scale [Up to 24 weeks post-randomization]

    The Parent vs. Anorexia Scale measures parental self-efficacy in relation to adolescent eating disorders via 7 items on a 4-point Likert scale. Higher scores indicate higher self-efficacy.

  3. General Self Efficacy Scale [Up to 24 weeks post-randomization]

    The General Self Efficacy Scale is a 10-item survey that assess perceived general self-efficacy across a broad range of stressful or challenging demands. Items are rated from 1-4, with higher scores reflect greater self-efficacy.

  4. Positive and Negative Affect Scale for Children [Up to 24 weeks post-randomization]

    The Positive and Negative Affect Scale for Children is a 30-item self-report measure of positive and negative affect. Items are rated from 1-5 with higher scores reflecting more intense emotions.

  5. Eating Disorder Symptom Impact Scale [Up to 24 weeks post-randomization]

    The Eating Disorder Symptom Impact Scale is a 24-item questionnaire that measures carers' perceptions of the emotional, psychological, and tangible impact of caring for someone with an eating disorder. 50 Items are measured on a 5-point Likert scale with higher scores indicating higher perceived burden during the previous month. The measure comprises five subscales measuring burden related to guilt, confrontational behaviors, binge-purge difficulties, mealtime difficulties, and illness awareness.

  6. Fear of Food Measure [Up to 24 weeks post-randomization]

    The Fear of Food Measure is a 33-item scale assessing mealtime anxiety using 3 subscales: anxiety about eating, food avoidance behavior, and feared concerns. Items are scored from 1-7 with higher scores reflecting greater fear of food.

  7. Eating Disorder Fear Questionnaire [Up to 24 weeks post-randomization]

    The Eating Disorder Fear Questionnaire assesses eating disorder-related fears and anxieties, specifically towards food and weight/shape. It includes 20 items scored from 1-7, with higher scores reflecting greater eating disorder-related fears.

  8. Child & Adolescent Symptom Inventory (CASI) [Up to 24 weeks post-randomization]

    The Child & Adolescent Symptom Inventory (CASI) parent-version will be used to identify potential psychiatric co-morbidities. The CASI combines two well-developed and widely-used scales, the Child Symptom Inventory (CSI) and Adolescent Symptom Inventory (ASI) to assess common mental and behavioral disordered in children ages 5 - 18. Symptoms are scored on a scale of 0 (never) to 3 (very often), with higher scores indicating more severe symptoms of psychiatric co-morbidities.

  9. Child Depression Inventory (CDI) [Up to 24 weeks post-randomization]

    The CDI is a widely-used measure for assessing depressive symptoms in youth. The CDI is well-established in terms of its test-retest reliability, internal consistency, and construct validity. It has been found to correlate modestly with clinician reports of depression, and to distinguish between children with depression and those with other forms of psychopathology. Items are scored from 1 to 3, with higher scores indicating more depressive symptoms.

  10. Eating Disorder Examination Questionnaire (EDE-Q) [Up to 24 weeks post-randomization]

    The Eating Disorder Examination-Questionnaire is a self-report questionnaire assessing eating pathology, including dietary restraint, and concerns about eating, shape, and weight. The EDE-Q assesses the frequency and severity of diagnostic symptoms of eating disorders using 4 subscales: restraint, eating concern, shape concern, and weight concern. Higher subscale and global scores indicate higher frequency and severity of eating disorder symptomology.

  11. Difficulties in Emotion Regulation Scale (DERS-18) [Up to 24 weeks post-randomization]

    The DERS-18 is a self-report 18-item measure of emotion regulation abilities. The scale is rated on a 5-point Likert scale from "almost never" to "almost always", with higher scores indicating higher emotion dysregulation. It is found to have good reliability and validity.

  12. Rosenberg Self-Esteem Scale (RSES) [Up to 24 weeks post-randomization]

    The Rosenberg Self-Esteem Scale is a child-reported measure of global self-esteem. Scores range from 0-30, with higher scores indicating higher self-esteem. The RSE has good reliability and validity in youth samples.

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Meets criteria for AN or atypical AN according to DSM-5 diagnostic criteria.

  • Currently living at home with caregivers who are willing to engage in family treatment.

  • Medically stable for outpatient treatment according to the recommended thresholds of the American Academy of Pediatrics and the Society of Adolescent Medicine (e.g., ≥75% of expected body weight, heartrate ≥50 beats per minute) and receiving medical monitoring from a clinician throughout treatment.

  • If on psychotropic medication, meets all eligibility criteria while on stable dose of psychotropic medication for a co-morbid condition.

  • Available for follow-up.

Exclusion Criteria:
  • Associated physical illness that necessitates hospitalization.

  • Psychotic illness/other mental illness requiring hospitalization.

  • Current dependence on drugs or alcohol.

  • Physical conditions (e.g. diabetes mellitus, pregnancy) known to influence eating or weight.

  • Concurrent involvement in other psychological treatment for an eating disorder.

  • Developmental delay that would preclude participation in the intervention.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Pittsburgh Pittsburgh Pennsylvania United States 15213
2 Gateway Healthcare Pawtucket Rhode Island United States 02860
3 The Providence Center Providence Rhode Island United States 02906

Sponsors and Collaborators

  • University of Pittsburgh
  • National Institute of Mental Health (NIMH)
  • Lifespan
  • Rhode Island College

Investigators

  • Principal Investigator: Andrea B Goldschmidt, Ph.D., The University of Pittsburgh

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Andrea Goldschmidt, Associate Professor, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT05184556
Other Study ID Numbers:
  • STUDY21070053
  • R34MH123589
First Posted:
Jan 11, 2022
Last Update Posted:
Jul 5, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 5, 2022